Remove topics federal-trade-commission-ftc
article thumbnail

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley M&A

Of course, withstanding this scrutiny does not come without time, commitment and expense – and it does not mean that deals with significant product or product candidate overlaps that are inconsistent with the revised FTC/DOJ Merger Guidelines will receive regulatory approvals.

M&A 52